Inhibikase Therapeutics Inc. reported its financial results for the first quarter ending March 31, 2025, showcasing a significant increase in net loss compared to the previous year. The company reported a net loss of $13.7 million for the quarter, which is a considerable increase from the $4.6 million net loss in the same period in 2024. Research and development expenses also rose sharply to $10.5 million from $2.8 million in the previous year, largely due to a $7.4 million non-cash charge related to the acquisition of CorHepta. The company's selling, general, and administrative expenses increased to $5.2 million from $2.0 million in 2024. As of March 31, 2025, Inhibikase had $93.2 million in cash, cash equivalents, and marketable securities. In business developments, the company has been advancing its lead candidate, IKT-001, into a late-stage clinical trial program for pulmonary arterial hypertension (PAH). The company is preparing to finalize the study design for a Phase 2b clinical study of IKT-001 in PAH and expects to initiate this study in the second half of 2025. The company recently appointed several key executives, including a new CEO, President and Head of Research & Development, Chief Scientific Officer, and Chief Financial Officer, to strengthen its leadership team.